Jeffrey Hackman
Vermögen: 634 510 $ am 31.07.2026
Vermögen: 634 510 $ am 31.07.2026
Jeffrey S Hackman is currently the Chairman & Chief Executive Officer at Comera Life Sciences, Inc. and the Chief Executive Officer & Director at Fennec Pharmaceuticals, Inc. Previously, he held positions as the Chairman, President & Chief Executive Officer at Comera Life Sciences Holdings, Inc., Chief Operating Officer & Director at Leadiant Biosciences, Inc., Chief Operating Officer & Director at Sigma-tau Healthscience USA, Inc., SVP-US Internal Medicine & Oncology franchise at Shire Plc, Vice President & Head-North America Region at Baxalta US, Inc., and Chief Executive & Operating Officer, Executive VP at Novelion Therapeutics, Inc. He obtained his undergraduate degree from Lycoming College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.08.2026 | 66.302 ( 0,19 % ) | 634 510 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Vorstandsvorsitzender | 16.08.2024 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biologic medicines | Vorstandsvorsitzender | 08.09.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| COMERA LIFE SCIENCES HOLDINGS, INC. | Vorstandsvorsitzender | 31.01.2024 |
| NOVELION THERAPEUTICS INC. | Vorstandsvorsitzender | 20.11.2018 |
Sigma-tau Healthscience USA, Inc.
Sigma-tau Healthscience USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation | Geschäftsführer | - |
Baxalta US, Inc.
Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Corporate Officer/Principal | - |
| SHIRE | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Fennec Pharmaceuticals, Inc.
Fennec Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutic products which dedicated to improving the lives of children with cancer who experience hearing loss | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Lycoming College
Lycoming College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Health Technology |
Baxalta US, Inc.
Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Health Technology |
Novelion Therapeutics, Inc.
Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Sigma-tau Healthscience USA, Inc.
Sigma-tau Healthscience USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biologic medicines | Health Technology |
Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen